IsoRay, Inc. (AMEX: ISR) announced today that it has successfully
shipped the first set of Cesium-131 brachytherapy seeds to a Canadian
customer for the purpose of furthering research and development of
Cesium-131 in Canada. Cesium-131 is currently approved by Health Canada
for the treatment of low-risk prostate cancers and has been cleared by
the US FDA for treatment of a wide variety of malignant disease (e.g.
prostate, head and neck, brain, breast, lung, eye, etc.).
“Inter V Medical, our distributor, brings to IsoRay
Medical a team of nine dedicated sales professionals strategically
placed across Canada with exclusive rights to sell Cesium-131
brachytherapy seeds. Inter V Medical has been bringing new medical
technologies, including brachytherapy and related products, to the
Canadian market for nearly twenty years.”
IsoRay Medical, in conjunction with its Canadian distribution partner,
Inter V Medical, looks forward to expanding the application of
Cesium-131 for other cancer treatment areas of the body. IsoRay is
seeking additional clinical evidence to allow Health Canada to approve
expanded indications for use of Cesium-131 for other malignant disease
locations. The goal is to obtain approvals for a wide variety of
malignant disease sites (as has already been obtained in the United
States).
Dwight Babcock, Chairman and CEO, stated, “We are very excited to take
this first step in gathering clinical data to support the expanded use
of Cesium-131 in Canada. We have experienced successful treatments of
numerous cancers here in the US, such as lung, head and neck, and colon
cancers, and look forward to bringing this technology to physicians in
Canada to use in treating their patients. We are working closely with
our distribution partner Inter V Medical to expedite the penetration of
the Canadian market.”
Babcock continued, “Inter V Medical, our distributor, brings to IsoRay
Medical a team of nine dedicated sales professionals strategically
placed across Canada with exclusive rights to sell Cesium-131
brachytherapy seeds. Inter V Medical has been bringing new medical
technologies, including brachytherapy and related products, to the
Canadian market for nearly twenty years.”
Air pollution linked to head and neck cancer risk